Cargando…
Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future
Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the r...
Autores principales: | Rihackova, Eva, Rihacek, Michal, Vyskocilova, Maria, Valik, Dalibor, Elbl, Lubomir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499183/ https://www.ncbi.nlm.nih.gov/pubmed/37711551 http://dx.doi.org/10.3389/fcvm.2023.1243531 |
Ejemplares similares
-
Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients
por: Rihacek, Michal, et al.
Publicado: (2022) -
Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
por: Li, Mo-Yun, et al.
Publicado: (2022) -
LightCycler SeptiFast technology in patients with solid malignancies: clinical utility for rapid etiologic diagnosis of sepsis
por: Dubská, Lenka, et al.
Publicado: (2012) -
B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia
por: Rihacek, Michal, et al.
Publicado: (2015) -
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)